Imatinib Eg Labo (Imatinib)

Imatinib is a tyrosine kinase inhibitor used in hematologic and solid‑tumor indications.

• Chronic myeloid leukemia: provides disease control by inhibiting BCR‑ABL driven proliferation.
• Gastrointestinal stromal tumor: induces tumor shrinkage and prolongs progression‑free survival.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia: offers targeted therapy to improve remission rates.

• Imatinib selectively binds to the ATP‑binding site of the BCR‑ABL fusion protein and other related tyrosine kinases such as c‑KIT and PDGFR. This inhibition blocks downstream signaling pathways that drive malignant cell growth, leading to reduced proliferation and increased apoptosis of cancerous cells.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the ankles.
• Muscle cramps: intermittent skeletal muscle discomfort.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools, usually self‑limiting.
• Rash: mild skin eruption.

Serious or Rare Side Effects

• Neutropenia: significant reduction in white blood cells.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiac failure: signs of reduced cardiac output.
• Severe bleeding: gastrointestinal or intracranial hemorrhage.
• Pulmonary hypertension: elevated pressure in lung arteries.
• Anaphylaxis: acute allergic reaction requiring emergency care.

Patients should be monitored for safety and efficacy throughout therapy.

• Monitor blood counts: perform regular complete blood count assessments.
• Assess liver function: check hepatic enzymes before and during treatment.
• Evaluate cardiac status: baseline and periodic echocardiograms for at‑risk patients.
• Avoid use in known hypersensitivity: discontinue if severe allergic reaction occurs.
• Counsel on pregnancy risks: discuss potential fetal effects with women of childbearing potential.
• Store at below 25°C: keep in the original packaging, protect from moisture and light.

Imatinib may interact with several concomitant medicines, requiring clinical attention.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib plasma levels.
• Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic exposure.
• Antacids containing aluminum or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• CYP3A4 substrates (e.g., warfarin, midazolam): may require dose adjustments.
• QT‑prolonging agents (e.g., sotalol, quinidine): monitor cardiac rhythm.
• Vaccines (live attenuated): assess timing relative to therapy.